menu search

ONCY / Oncolytics Biotech Inc. (ONCY) Q3 2023 Earnings Call Transcript

Oncolytics Biotech Inc. (ONCY) Q3 2023 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, IR Matt Coffey - President & CEO Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. Kirk Look - CFO Conference Call Participants Louise Chen - Cantor John Newman - Canaccord Soumit Roy - JonesTrading Operator Good morning, and welcome to Oncolytics Biotech's Third Quarter 2023 Conference Call. All participants are now in listen-only mode. Read More
Posted: Nov 3 2023, 21:05
Author Name: Seeking Alpha
Views: 022788

ONCY News  

Oncolytics Biotech Inc. (ONCY) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 3, 2023

Oncolytics Biotech Inc. (ONCY) Q3 2023 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, IR Mat more_horizontal

After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)

By Zacks Investment Research
August 17, 2023

After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)

The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this more_horizontal

Oncolytics Biotech Inc. (ONCY) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 14, 2023

Oncolytics Biotech Inc. (ONCY) Q2 2023 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Jon Patton - Director-Investor more_horizontal

Oncolytics: Proof Of Concept In 2 Large Market Indications

By Seeking Alpha
July 3, 2023

Oncolytics: Proof Of Concept In 2 Large Market Indications

Positive results achieved, in using pelareorep + paclitaxel for the treatment of HR+/HER2- metastatic breast cancer patients, in the phase 2 BRACELET- more_horizontal

Oncolytics Biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancreatic cancer trial

By Market Watch
June 22, 2023

Oncolytics Biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancreatic cancer trial

The stock of Oncolytics Biotech Inc. ONCY, +23.25% soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selecte more_horizontal

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

By PRNewsWire
April 12, 2023

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

SAN DIEGO and CALGARY, AB , April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Off more_horizontal

Oncolytics Biotech Inc. (ONCY) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 3, 2023

Oncolytics Biotech Inc. (ONCY) Q4 2022 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q4 2022 Earnings Conference Call March 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, Investor more_horizontal

New Strong Buy Stocks for January 18th

By Zacks Investment Research
January 18, 2023

New Strong Buy Stocks for January 18th

DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022. more_horizontal


Search within

Pages Search Results: